Trials / Completed
CompletedNCT00669591
A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
A Phase II Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Peregrine Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the overall response to a combination of bavituximab and docetaxel in patients with advanced breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bavituximab | Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-06-01
- Completion
- 2010-08-01
- First posted
- 2008-04-30
- Last updated
- 2017-04-21
Locations
4 sites across 1 country: Georgia
Source: ClinicalTrials.gov record NCT00669591. Inclusion in this directory is not an endorsement.